BDTX Earnings Black Diamond Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–26 of 26
| Q2 2026 | 2026-06-30 | -0.33 | 2026-08-05 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.16 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | 0.39 | 2026-03-16 | 10-K |
| Q3 2025 | 2025-09-30 | 0.65 | 2025-11-06 | 10-Q |
| Q2 2026 | 2025-06-30 | 0.80 | 2026-08-05 | 10-Q |
| Q1 2026 | 2025-03-31 | 0.98 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -1.27 | 2026-03-16 | 10-K |
| Q3 2025 | 2024-09-30 | -0.99 | 2025-11-06 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.71 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.35 | 2025-05-12 | 10-Q |
| FY 2024 | 2023-12-31 | -1.88 | 2025-03-06 | 10-K |
| Q3 2024 | 2023-09-30 | -1.54 | 2024-11-05 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.09 | 2024-08-06 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.57 | 2024-05-09 | 10-Q |
| FY 2023 | 2022-12-31 | -2.52 | 2024-03-12 | 10-K |
| Q3 2023 | 2022-09-30 | -1.93 | 2023-11-06 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.33 | 2023-08-11 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.70 | 2023-05-09 | 10-Q |
| FY 2022 | 2021-12-31 | -3.47 | 2023-03-09 | 10-K |
| Q3 2022 | 2021-09-30 | -2.76 | 2022-11-08 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.79 | 2022-08-09 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.84 | 2022-05-11 | 10-Q |
| FY 2021 | 2020-12-31 | -2.05 | 2022-03-17 | 10-K |
| Q3 2021 | 2020-09-30 | -1.42 | 2021-11-08 | 10-Q |
| Q2 2021 | 2020-06-30 | -0.92 | 2021-08-12 | 10-Q |
| Q1 2021 | 2020-03-31 | -0.51 | 2021-05-07 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.